Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

Autor: Jiyuan Chen, Wenjun Jiang, Yongfang Yuan, Yuanyuan Wang, Yuan Gao, Chunai Gong
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
lcsh:Medical technology
lcsh:Biotechnology
Biomedical Engineering
Mice
Nude
Pharmaceutical Science
Medicine (miscellaneous)
Antineoplastic Agents
Bioengineering
Applied Microbiology and Biotechnology
Androgen deprivation therapy
Mice
chemistry.chemical_compound
Prostate cancer
In vivo
Cell Line
Tumor
lcsh:TP248.13-248.65
Nitriles
Phenylthiohydantoin
LNCaP
medicine
Enzalutamide
Animals
Humans
Particle Size
Cell Proliferation
Castration-resistant prostate cancer
Mice
Inbred BALB C
Research
Prostatic Neoplasms
Androgen Antagonists
Graphene quantum dot derivate
medicine.disease
Graphene quantum dot
Bioavailability
Drug Liberation
Prostatic Neoplasms
Castration-Resistant
Redox-sensitive
chemistry
lcsh:R855-855.5
Drug Resistance
Neoplasm
Benzamides
Cancer research
Nanoparticles
Molecular Medicine
Graphite
Nanocarriers
Zdroj: Journal of Nanobiotechnology, Vol 18, Iss 1, Pp 1-12 (2020)
Journal of Nanobiotechnology
ISSN: 1477-3155
Popis: Background Enzalutamide (Enz) has shown limited bioavailability via oral administration. Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18–24 months of androgen deprivation therapy. The nonsteroidal anti-androgen enzalutamide (Enz) used in the treatment of prostate cancer has shown limited bioavailability via oral administration. Therefore, we developed a multifunctional enzalutamide-loaded graphene oxide nanosystem (TP-GQDss/Enz) for CRPC intravenous treatment, with high drug loading efficiency. Methods Aminated graphene quantum dots (GQDs) were first cross-linked via disulfide bonds into a graphene quantum dot derivative of approximately 200 nm (GQDss), which was further functionalized with a tumour-targeting peptide and PEG to form TP-GQDss. Enz was loaded into TP-GQDss for in vitro and in vivo study. Results The results showed that high drug-loading efficiency was achieved by TP-GQDss via π–π electron interaction. TP-GQDss could be rapidly internalized by CRPC cells via endocytosis. Moreover, Enz in TP-GQDss could inhibit the growth of C4-2B and LNCaP prostate cancer cell lines in vitro. Further, TP-GQDss exhibited an enhanced cancer-targeting ability and alleviated the side effects of Enz in vivo. Conclusions The multifunctional nanocarrier constructed here could accomplish controlled Enz release and serve as an intravenous therapy platform for CRPC.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje